Objective To investigate the clinical efficacy of Yinhuo Guiyuan moxibustion as an adjunc-tive therapy to Yaotongning Capsules in treating kidney deficiency-related lumbago in patients with stage 3-4 chronic kidney disease.Methods Sixty patients with stage 3-4 chronic kidney disease admitted from Janu-ary 2021 to June 2023 were randomly divided into a control group and an observation group,with 30 cases in each group.Both groups received basic treatment interventions during the study period.The control group re-ceived Yaotongning Capsules orally,while the observation group received additional Yinhuo Guiyuan moxibus-tion therapy.Clinical efficacy,pain scores,renal function indicators,satisfaction scores,and adverse reaction rates were compared between the two groups.Results The total effective rate was significantly higher in the observation group(93.33％)than in the control group(73.33％,P＜0.05).At the 4th,8th,and 12th weeks of treatment,the VAS scores of both groups were lower than baseline values,with the observation group dem-onstrating significantly lower scores compared to the control group at the same time points(P＜0.05).After treatment,both groups showed reductions in BUN,Scr,and 24hUP levels,with the observation group showing lower levels than the control group(P＜0.05).The observation group demonstrated higher satisfaction scores than the control group(P＜0.05).No significant difference was found in adverse reaction rates between groups(x2=0.218,P=0.640).Conclusion Yinhuo Guiyuan moxibustion combined with Yaotongning Cap-sules is effective in treating stage 3-4 chronic kidney disease patients,effectively alleviating low back pain,improving renal function indicators,enhancing treatment satisfaction,with lower incidence of adverse reac-tions.

OBJECTIVE To construct the quantitative evaluation system of regional clinical pharmacists’ professional ability， and provide reference for the evaluation of regional clinical pharmacists’ professional ability. METHODS Twenty-one experts from 18 hospitals in Chongqing were consulted to construct a professional ability index system for clinical pharmacists. TOPSIS model was used to calculate and obtain the expert authority index （EI）， and the weighted averaging method was used to construct the judgment matrix. Analytic hierarchy process （AHP） was used to calculate the weights of all indicators for establishing a quantitative evaluation system of regional clinical pharmacists’ professional ability according to the weights of each item. RESULTS The results of TOPSIS showed that the EI range was 0.010-0.100， and the relative authority of experts was distinguished and measured effectively. The results of AHP showed that the judgment matrix of the quantitative evaluation system met the requirements of consistency test （consistency test index CR＜0.1）. Finally， a quantitative evaluation system for regional clinical pharmacists’ professional ability was established， including 6 sub-objective items （basic ability， clinical practice ability， coordination and communication ability， publicity ability， scientific research and teaching ability， continuous improvement ability） and 25 index items （such as educational background， professional title， clinical pharmacy working years， daily theoretical skills assessment， information ability level， medication education， etc.）. CONCLUSIONS A quantitative evaluation system of regional clinical pharmacists’ professional ability has been established. Our study provides a theoretical reference for the quantitative evaluation and optimal management of regional clinical pharmacists.

A 56-year-old male patient with lymphoma received anti-tumor treatments with treprizumab (intravenous infusion of 240 mg once every 21 days) combined with rituximab, gemcitabine, and oxaliplatin. On day 5 after the first treatment of treprizumab, the patient developed rash all over the body and a large area of erythema on the trunk and limbs, accompanied by pruritus and pain, and the exfoliation area of the whole body was more than 30%. Laboratory tests showed white blood cell count 12.4×10 9/L, neutrophil count 11.5×10 9/L, erythrocyte sedimentation rate 162 mm/1 h, C-reactive protein 74 mg/L, and procalcitonin 1.09 μg/L. The patient had received antineoplastic therapy with rituximab, gemcitabine, and oxaliplatin and no skin reaction occurred. Stevens-Johnson syndrome induced by treprizumab was considered. Protective isolation care and symptomatic treatments such as glucocorticoid, immunoglobulin, and anti-infection were given. After 23 days of treatments, the patient was improved, and the skin ulceration area decreased to 10%. After 31 days of treatments, regenerated skin appeared under most of the ulcerated skin, and laboratory tests showed erythrocyte sedimentation rate 46 mm/1 h, C-reactive protein 15 mg/L, and procalcitonin 0.04 μg/L.

A 56-year-old male patient with lymphoma received anti-tumor treatments with treprizumab (intravenous infusion of 240 mg once every 21 days) combined with rituximab, gemcitabine, and oxaliplatin. On day 5 after the first treatment of treprizumab, the patient developed rash all over the body and a large area of erythema on the trunk and limbs, accompanied by pruritus and pain, and the exfoliation area of the whole body was more than 30%. Laboratory tests showed white blood cell count 12.4×10 9/L, neutrophil count 11.5×10 9/L, erythrocyte sedimentation rate 162 mm/1 h, C-reactive protein 74 mg/L, and procalcitonin 1.09 μg/L. The patient had received antineoplastic therapy with rituximab, gemcitabine, and oxaliplatin and no skin reaction occurred. Stevens-Johnson syndrome induced by treprizumab was considered. Protective isolation care and symptomatic treatments such as glucocorticoid, immunoglobulin, and anti-infection were given. After 23 days of treatments, the patient was improved, and the skin ulceration area decreased to 10%. After 31 days of treatments, regenerated skin appeared under most of the ulcerated skin, and laboratory tests showed erythrocyte sedimentation rate 46 mm/1 h, C-reactive protein 15 mg/L, and procalcitonin 0.04 μg/L.